Equity Profile

AMRX

Amneal Pharmaceuticals, Inc.

Health CarePharmaceuticals$4.4B

Apr22Wed

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:22 AM EDT

Amneal Pharmaceuticals Beats on EPS, Stock Down 1.5%

Metric	Actual	Expected	Surprise
EPS	$0.27	$0.17	+8.00%
Revenue	—	$717M	—

management commentary, guidance changes, and full analysis available with Pro.

Amneal Pharmaceuticals Beats on EPS, Stock Down 1.5%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.27	$0.17	+8.00%
Revenue	—	$717M	—

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so the analysis is based solely on numerical results.

What It Means

Amneal Pharmaceuticals reported better-than-expected earnings per share, which indicates stronger profitability than analysts anticipated. However, the stock fell by 1.5% following the report, likely due to the lack of revenue information and absence of guidance, leaving investors uncertain about future performance.

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$0.17

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$717M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals. With a market cap of $4 billion, it plays a significant role in the pharmaceutical sector, focusing on providing affordable medications to patients and healthcare providers.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

In Q4 2025, Amneal reported an EPS of $0.21, surpassing expectations by 27.27%. However, the stock fell 4.69% the following day, indicating mixed market reactions despite the positive earnings surprise.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Amneal to report solid earnings this quarter, with a consensus EPS of $0.17 and revenue of $717 million. The market is closely watching for any surprises that could impact stock performance.

Bull Case

If Amneal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its market position and lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$0.17

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$717M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal's EPS exceed the consensus estimate of $0.17?

A beat on EPS could reinforce confidence in the company's profitability and growth trajectory.

What guidance will management provide regarding future revenue growth?

Future revenue guidance will be crucial for assessing the company's market outlook and potential for continued success.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amneal's ability to capitalize on recent market trends, particularly in generic drug demand.

Supporting Evidence

Amneal has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent industry trends show increasing demand for generics, which could benefit Amneal significantly.

Key Risk

If Amneal's revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amneal can maintain its growth momentum in a competitive pharmaceutical landscape.

Bull Confirmed If

An EPS of $0.19 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.15 would support the bear case, raising concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±25.1%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±25.1% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.0%

Calls (2K)P/C Ratio: 0.04Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could rise by around 0.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

Should the company miss estimates, the stock could decline by approximately 3.46%, indicating a strong negative reaction from the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on competitive pressures in the generic market.
3Insights into cost management strategies and their impact on margins.
4Details on market share changes in key therapeutic areas.
5Any commentary on regulatory challenges or opportunities.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr20

CLFReported

Cleveland-Cliffs Inc.

RecapView

Apr20

BOHReported

Company Snapshot

Amneal Pharmaceuticals, Inc. is a healthcare company that develops and manufactures generic and specialty pharmaceuticals....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

$0.17

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$717M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+34.60%

Avg Stock Reaction

-0.24%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Amneal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its market position and lead to a significant decline in stock price.

Key Metrics to Watch

EPS

$0.17

Earnings per share (EPS) is a key indicator of the company's profitability and financial health.

Revenue

$717M

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Amneal's EPS exceed the consensus estimate of $0.17?

A beat on EPS could reinforce confidence in the company's profitability and growth trajectory.

What guidance will management provide regarding future revenue growth?

Future revenue guidance will be crucial for assessing the company's market outlook and potential for continued success.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Amneal's ability to capitalize on recent market trends, particularly in generic drug demand.

Supporting Evidence

Amneal has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.

The options market is pricing in a larger move than historical averages, suggesting heightened expectations.

Recent industry trends show increasing demand for generics, which could benefit Amneal significantly.

Key Risk

If Amneal's revenue growth exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Amneal can maintain its growth momentum in a competitive pharmaceutical landscape.

Bull Confirmed If

An EPS of $0.19 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $0.15 would support the bear case, raising concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±25.1%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings report.

Options are pricing ±25.1% while AMRX has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.0%

Calls (2K)P/C Ratio: 0.04Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: X of Y (Z%)

This setup has occurred 30 times across Health Care in the last 2 years. The average absolute 1-day move is 4.6%, with a raw directional average of +0.8% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Amneal beats expectations, history suggests the stock could rise by around 0.71%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.

Miss

Should the company miss estimates, the stock could decline by approximately 3.46%, indicating a strong negative reaction from the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or pipeline developments.
2Management's commentary on competitive pressures in the generic market.
3Insights into cost management strategies and their impact on margins.
4Details on market share changes in key therapeutic areas.
5Any commentary on regulatory challenges or opportunities.